Log In
BCIQ
Print this Print this
 

SSX2 TCR

  Manage Alerts
Collapse Summary General Information
Company Kite Pharma Inc.
DescriptionT cell receptor targeting synovial sarcoma X breakpoint 2 (SSX2)
Molecular Target Synovial sarcoma X breakpoint 2 (SSX2)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today